According to a new market report published by Transparency Market Research “Global Myasthenia Gravis Market (By Treatment- Drug Treatment; Cholinesterase Inhibitors, Monoclonal Antibodies, Chronic Immunomodulators, Rapid Immunotherapies; Plasmapheresis, Intravenous Immunoglobulin (Ivlg), and Thymectomy) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The global myasthenia gravis market was valued at US$ 975.1 Mn in 2016 and is projected to expand at a CAGR of 10.1% during forecast period from 2017 to 2025 to reach US$ 2313.1 Mn in 2025.
Myasthenia gravis is autoimmune and extraordinary primary disease of neuromuscular transmission. Much has been learned about the immunopathology and pathophysiology of myasthenia gravis during the last 20 years. The common cause is an acquired immunological abnormality, though several cases result from genetic abnormalities at the neuromuscular transmission. An extensive range of potentially effective therapies are existing, most of which have suggestions to treat other autoimmune disorders.
Geographically the market has been studied for four regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Each of these regions has been further segmented and analyzed for the respective major contributing countries. North America which includes the United States and Canada accounted for largest share in 2016 owing to rapidly growing incidence of myasthenia gravis. According to Center for Disease Control & Prevention the prevalence rate of myasthenia gravis is estimated to be 14 to 20 per 100,000 population in the United States, nearly 36,000 to 60,000 cases in the U.S. Though, diagnosis rate of myasthenia gravis is very low and the prevalence is probably higher.
Followed by North America, Europe accounts for second largest revenue contributor to the global myasthenia gravis market. The Europe market has been sub-segmented into U.K., France, Germany, Italy, Spain, and Rest of Europe. Leading manufacturers are constantly investing in research and development to develop novel molecules for efficient treatment of myasthenia gravis. This factor is expected to drive the market growth during the forecast period. In 2017, Alexion Pharmaceuticals, Inc. announced the approval of Soliris (eculizumab) for the treatment of generalized myasthenia gravis in patients who are anti-acetylcholine receptor (AchR) antibody-positive. Moreover, According to “Ageing Report” published in 2015 by the European Commission, the percentage of people in Europe aged above 45 years is expected to increase from 21% in 2013 to 32% by 2060. This factor is likely to increase the demand for the treatment of myasthenia gravis in Europe.
Asia Pacific myasthenia gravis market is sub-segmented into China, India, Japan, Australia & New Zealand, and rest of Asia Pacific. Moreover, it is the fastest growing market for myasthenia gravis market globally with prevalence rate of 200-300 per million population in Asia Pacific region. Initiatives by governmental and non-governmental organizations such as Special Interest Group of Myasthenia Gravis in Asia (SIGMA) to increase awareness among people about myasthenia gravis is expected to propel the myasthenia gravis market in the region. Recently, a non-governmental organization SIGMA contributed a grant of USD 10,000 per annum to facilitate the early diagnosis of myasthenia gravis through laboratory tests run in the National University of Singapore. Latin America myasthenia gravis market is sub-segmented into Brazil, Mexico, and Rest of Latin America. Increasing government-aided health programs such as ‘Farmacia Popular’ aim to provide essential medications and drugs to people at reasonable prices in pharmacies across Brazil. This is expected to drive the myasthenia gravis market in the country during the forecast period.
Middle East & Africa myasthenia Gravis market is sub-segmented into GCC countries, South Africa, and Rest of Middle East & Africa. Economic disparity and political instability in the region is anticipated to hinder the growth of the market; however, recent government initiatives for promoting research and development in the GCC countries are seen as major drivers of the health care industry in the region.
The global myasthenia gravis market is largely consolidated, with several large global players and a few local players operating in the market. Leading players in the global myasthenia gravis market include are Alexion Pharmaceutical Inc., Avadel Pharmaceuticals, Plc. (Flamel Technologies), CSL Behring, Grifols, S.A., Baxter International, Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International, Inc. among others.
Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=387